Menu Search
Equities

Mevis Medical Solutions AG

M3Vd:EBT

Mevis Medical Solutions AG

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mevis Medical Solutions AG is a Germany-based provider of software and services for the medical image processing industry, and offers computer support for image-based medical diagnosis and therapy. The Company develops medical application software for industrial customers including turnkey applications, and also research laboratories. In addition to that, the Company operates an online academy and trains professionals, such as radiologists, in working with its products. The Company's software applications support various applicable imaging modalities, especially magnetic resonance tomography (MRT) and digital mammography, but also computer tomography (CT), tomosynthesis and digital sonography based on ultrasonics.

  • Revenue in EUR (TTM)17.64m
  • Net income in EUR5.75m
  • Incorporated2006
  • Employees111.00
  • Location
    Mevis Medical Solutions AGCaroline-Herschel-Str. 1BREMEN 28359GermanyDEU
  • Phone+49 421224950
  • Fax+49 42 122495999
  • Websitehttps://www.mevis.de/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.